2
|
Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S. Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2021; 62:1756-1760. [PMID: 33596765 DOI: 10.1080/10428194.2021.1881505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- S Fodil
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - E Raffoux
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - P Y Dumas
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - Y Desbrosses
- Service d'Hématologie, CHRU Jean Minjoz, Besançon, France
| | - F Larosa
- Service d'Hématologie, CHU de Dijon, Dijon, France
| | - S Chantepie
- Service d'Hématologie, Institut d'Hématologie de Basse-Normandie CHU de Caen, Caen, France
| | - M V Larcher
- Service d'Hématologie, Hospices civils de Lyon, CHU de Lyon, Lyon, France
| | - J B Mear
- Service d'Hématologie, CHU de Rennes - Hôpital Pontchaillou, Rennes, France
| | - P Peterlin
- Service d'Hématologie, CHU de Nantes, Nantes, France
| | - M Hunault-Berger
- Service des Maladies du Sang, Centre Hospitalier Universitaire, FHU GOAL, CRCINA, INSERM, Angers, France
| | - M A Hospital
- Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Morel
- Service d'Hématologie, Hôpital Pitié-Salpêtrière AP-HP, Paris, France
| | - N Lucas
- Service d'Hématologie, Institut Gustave Roussy, Villejuif, France
| | - V Vidal
- Service d'Hématologie, Hôpital Avicenne AP-HP, Bobigny, France
| | - C Salanoubat
- Service d'Hématologie, C.H. Sud Francilien, Corbeil-Essonnes, France
| | - J Michel
- Service d'Hématologie, C.H.R. - Hôpital Félix Maréchal, Metz-Thionville, France
| | - C Mediavilla
- Service d'Hématologie, Hôpital Saint-Antoine AP-HP, Paris, France
| | - M Ojeda-Uribe
- Service d'Hématologie, Groupe Hospitalier Régional Mulhouse Sud-Alsace, Mulhouse, France
| | - M Alexis
- Service d'Hématologie, CHR Orléans, Orléans, France
| | - J Frayfer
- Service d'Hématologie, Grand Hôpital de l'Est Francilien - Site de Meaux, Meaux, France
| | - M Carré
- Service d'Hématologie, CHU Grenoble Alpes, La Tronche, France
| | - N Maillard
- Service d'Hématologie, CHU de Poitiers, Poitiers, France
| | - R Redjoul
- Service d'Hématologie, CHU Henri Mondor, AP-HP et UPEC, Créteil, France
| | - A Banos
- Service d'Hématologie, Centre hospitalier de la côte basque, Bayonne, France
| | - M Detrait
- Service d'Hématologie, CHRU de Nancy, Nancy, France
| | - T Cluzeau
- Département d'Hématologie, Université Cote d'Azur, CHU de Nice, Nice, France
| | | | - D Chaoui
- Service d'Hématologie, CH d'Argenteuil, Argenteuil, France
| | - M Elassy
- Service d'Hématologie, CH d'Auxerre, Auxerre, France
| | - A Pigneux
- Service d'Hématologie, CHU Bordeaux, F-33000, Bordeaux, France
| | - H Dombret
- Service d'Hématologie adulte, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Récher
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | - S Bertoli
- Service d'Hématologie, CHU de Toulouse, Centre de Recherches en Cancérologie de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France
| | | |
Collapse
|
5
|
Validire P, Fermé C, Brice P, Diviné M, Gabarre J, Bouabdallah K, Fitoussi O, Chaoui D, Soussain C, Carde P, Decaudin D. A large multicentric study of gemcitabine-based regimen in relapsed or refractory Hodgkin lymphoma (HL) patients (pts). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18518 Background: The aim of this study was to assess the efficacy and safety of gemcitabine-based regimen in heavily pretreated HL pts. Methods: Relapsed or refractory HL pts treated with gemcitabine were retrospectively reviewed. Gemcitabine was used as a single agent or administered in combination with vinorelbine, oxaliplatine, doxorubicine, vinblastine, rituximab, and/or corticosteroids. Results: Fifty-five pts treated in 9 departments of clinical hematology between January 1999 and August 2006 were included in the study. Initial characteristics before gemcitabine administration were: nodular sclerosis in 84%; sex ratio M/F 1.1; median age 29 years (range: 15–85 years); advanced stage 84%; extranodal sites were lung, bone, liver, soft tissues, and bone marrow in 68%, 31%, 13%, 21%, and 4%, respectively; Hasenclever index lower than 3 in 20/43 cases (47%). At the end of the first front-line therapy (chemotherapy ± radiotherapy), 19 pts (35%) were in complete response (CR) in whom 13 relapsed within one year, 5 were in partial response (PR), and 31 pts were primary refractory (56%). Median number of previous chemotherapeutic regimen was 3 (range 1–8), 39 pts (71%) have received radiotherapy (RT), and 34 pts (62%) one or two autologous/allogenic stem cell transplantations (A/ASCT). Twenty-nine pts received gemcitabine alone with a median initial dose per injection of 750 mg/m2 (range: 180–1250 mg/m2); Gemcitabine was administered at an initial dose per injection of 1000 mg/m2 (range: 500–1250) in combination with vinorelbine in 10 pts, oxaliplatine in 13 pts in whom 4 with rituximab, and with others drugs in 3 pts. In both cases, the median number of combined gemcitabine regimen injections was 6 (range: 1–27). Toxicity was mainly hematological (75% of pts developed bi- or pancytopenia) or infectious (13%). Among all included pts, 6 were in CR (11%) and 5 in PR with an overall response rate of 20%. Among the 6 CR, 5 pts received thereafter A/ASCT and 2 pts RT, with 2 persistent CR at 16 and 44 months. In univariate analysis, none prognostic factor for response to gemcitabine was identified. Conclusions: This study, which constitutes one of the most important series, showed a mild efficacy of gemcitabine-based regimen in heavily pretreated HL patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Validire
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - C. Fermé
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - P. Brice
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - M. Diviné
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - J. Gabarre
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - K. Bouabdallah
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - O. Fitoussi
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - D. Chaoui
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - C. Soussain
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - P. Carde
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - D. Decaudin
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| |
Collapse
|
6
|
Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 2006; 95:253-9. [PMID: 16847470 PMCID: PMC2360653 DOI: 10.1038/sj.bjc.6603265] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with advanced acute myeloid leukaemia were included in this sequential Bayesian phase I dose-finding trial. A starting dose of 0.5 mg m−2 day−1 was explored with subsequent dose escalations of 1, 3, 5 and 6 mg m−2 day−1. Myelosuppression was constant. The MTD was estimated as the dose level of 5 mg m−2 day−1 for 9 consecutive days by s.c. route. Dose-limiting toxicities were hyperglycaemia with hyperosmolar coma at 3 mg m−2, and (i) one anasarque and haematemesis, (ii) one life-threatening pulmonary aspergillosis, (iii) one skin rash and (iv) one scalp pain at dose level of 5 mg m−2 day−1. The mean half-life of ssHHT was 11.01±3.4 h, the volume of distribution at steady state was 2±1.4 l kg−1 and the plasma clearance was 11.6±10.4 l h−1. Eleven of the 12 patients with circulating leukaemic cells had blood blast clearance, two achieved complete remission and one with blast crisis of CMML returned in chronic phase. The recommended daily dose of ssHHT on the 9-day schedule is 5 mg m−2 day−1.
Collapse
Affiliation(s)
- V Lévy
- Inserm CIC 9504, Centre d'Investigations Cliniques, Hôpital Saint Louis, AP-HP, 1 Avenue Claude Vellefaux, Paris 75475, France
- Inserm U717, Hôpital Saint Louis, Paris, France
- E-mail:
| | - S Zohar
- Inserm CIC 9504, Centre d'Investigations Cliniques, Hôpital Saint Louis, AP-HP, 1 Avenue Claude Vellefaux, Paris 75475, France
- Inserm U717, Hôpital Saint Louis, Paris, France
- Inserm U717, Département de Biostatistique et Infomatique Médicale, Hôpital Saint Louis, AP-HP, Paris, France
| | - C Bardin
- Service de Pharmacie Pharmacologie Toxicologie, Hôtel Dieu de Paris, AP-HP, Paris, France
| | - A Vekhoff
- Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, AP-HP, Paris, France
| | - D Chaoui
- Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, AP-HP, Paris, France
| | - B Rio
- Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, AP-HP, Paris, France
| | - O Legrand
- Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, AP-HP, Paris, France
| | - S Sentenac
- Service de Pharmacie Pharmacologie Toxicologie, Hôtel Dieu de Paris, AP-HP, Paris, France
| | - P Rousselot
- Service d'Hématologie Clinique, Hôpital Saint Louis, AP-HP, Paris France
| | - E Raffoux
- Service d'Hématologie Clinique, Hôpital Saint Louis, AP-HP, Paris France
| | - F Chast
- Service de Pharmacie Pharmacologie Toxicologie, Hôtel Dieu de Paris, AP-HP, Paris, France
| | - S Chevret
- Inserm U717, Hôpital Saint Louis, Paris, France
- Inserm U717, Département de Biostatistique et Infomatique Médicale, Hôpital Saint Louis, AP-HP, Paris, France
| | - J P Marie
- Département d'Hématologie et d'Oncologie Médicale, Hôtel Dieu, AP-HP, Paris, France
| |
Collapse
|